Dr Reddy’s Laboratories announced today that it launched Valganciclovir tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE{+®} (Valganciclovir) tablets, in the US market on December 15.
The anti-viral drug has got approval from the United States Food & Drug Administration (USFDA).
The Valcyte tablets brand had US sales of approximately $440 million MAT for the most recent 12 months ending in October 2014, according to IMS Health.
Dr Reddy’s Valganciclovir tablets, USP in 450 mg is available in bottle counts of 60, the Hyderabad-based company said in a press release.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.